Review of pharmacological therapies in fibromyalgia syndrome

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Häuser, Winfried ^a,b   Walitt, Brian ^c   Fitzcharles, Mary Ann ^d   Sommer, Claudia ^e  

^a KLINIKUM SAARBRÜCKEN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CANNABINOID; CYCLOBENZAPRINE; DULOXETINE; GROWTH HORMONE; HORMONE; MILNACIPRAN; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PREGABALIN; QUETIAPINE; TRAMADOL;

CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FIBROMYALGIA; HUMAN; META ANALYSIS (TOPIC); PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW;

FIBROMYALGIA; HUMANS;

EID: 84892507406     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4441     Document Type: Review

References (52)

1. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russel IJ, Sheon RP. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172. 10.1002/art.1780330203, 2306288.
2. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubère JP, Le Lay K, Taieb C, Matucci-Cerinic M. Prevalence of fibromyalgia: a survey in five European countries. Semin Arthritis Rheum 2010, 39:448-453. 10.1016/j.semarthrit.2008.12.003, 19250656.
3. Ablin JN, Oren A, Cohen S, Aloush V, Buskila D, Elkayam O, Wollman Y, Berman M. Prevalence of fibromyalgia in the Israeli population: a population-based study to estimate the prevalence of fibromyalgia in the Israeli population using the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ). Clin Exp Rheumatol 2012, 30:39-43.
4. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. J Rheumatol 2011, 38:1113-1122. 10.3899/jrheum.100594, 21285161.
5. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care Res (Hoboken) 2013, 65:777-785.
6. Häuser W, Zimmer C, Felde E, Köllner V. What are the key symptoms of fibromyalgia? Results of a survey of the German Fibromyalgia Association. Schmerz 2008, 22:176-183. In German, 10.1007/s00482-007-0602-z, 18210165.
7. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G. The comptive economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm 2012, 18:415-426.
8. Wolfe F, Anderson J, Harkness D, Bennett RM, Caro XJ, Goldenberg DL, Russell IJ, Yunus MB. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560-1570. 10.1002/art.1780400904, 9324009.
9. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 8:27. 10.1186/1471-2474-8-27, 1829161, 17349056.
10. Häuser W, Jung E, Erbslöh-Möller B, Gesmann M, Kühn-Becker H, Petermann F, Langhorst J, Thoma R, Weiss T, Wolfe F, Winkelmann A. German fibromyalgia consumer reports - a crosssectional survey. BMC Musculoskelet Disord 2012, 13:74. 10.1186/1471-2474-13-74, 3444387, 22607517.
11. Wilson AL. Influencing prescribers. Top Hosp Pharm Manage 1994, 14:40-46.
12. Frost & Sullivan Healthcare and Life Sciences Consulting Group Assessment of the U.S. Fibromyalgia Market in Support of S1 Filing (Phase 2). [http://www.sec.gov/Archives/edgar/data/1430306/000101376211002697/exh9902.pdf], Frost & Sullivan Healthcare and Life Sciences Consulting Group.
13. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, Pereira JX, Abbey S, Choinière M, Ko G, Moulin DE, Panopalis P, Proulx J, Shir Y. National Fibromyalgia Guideline Advisory Panel 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: Executive Summary. Pain Res Manag 2013, 18:119-126. National Fibromyalgia Guideline Advisory Panel.
14. Eich W, Häuser W, Arnold B, Bernardy K, Brückle W, Eidmann U, Klimczyk K, Köllner V, Kühn-Becker H, Offenbächer M, Settan M, von Wachter M, Petzke F. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften Fibromyalgia syndrome. General principles and coordination of clinical care and patient education. Schmerz 2012, 26:268-275. 10.1007/s00482-012-1167-z, 22760459, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften.
15. Häuser W, Bernardy K, Wang H, Kopp I. Methodological fundamentals of the development of the guideline. Schmerz 2012, 26:232-246. In German, 10.1007/s00482-012-1189-6, 22760456.
16. Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, Uçeyler N, Winkelmann A, Winter E, Bär KJ. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline. Schmerz 2012, 26:297-310. 10.1007/s00482-012-1172-2, 22760463, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften.
17. Häuser W, Urrútia G, Tort S, Uçeyler N, Walitt B. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2013, 1:CD010292.
18. Tort S, Urrútia G, Nishishinya MB, Walitt B. Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome. Cochrane Database Syst Rev 2012, 4:CD009807.
19. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012, 12:CD008242.
20. Häuser W, Wolfe F, Tölle T, Üçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs 2012, 26:297-307. 10.2165/11598970-000000000-00000, 22452526.
21. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev 2009, 3:CD007076.
22. Üçeyler N, Sommer C, Waliit B, Häuser W. Anticonvulsants in fibromyalgia syndrome. Cochrane Database Syst Rev 2013, 10:CD010782.
23. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analyses. Int Clin Psychopharmacol 2005, 20:49-52. 10.1097/00004850-200501000-00010, 15602117.
24. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain 2013, 17:581-586. 10.1002/j.1532-2149.2012.00234.x, 23169685.
25. Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R. Real-world role of tricyclic antidepressants in the treatment of fibromyalgia. Pain Pract 2012, 12:533-540. 10.1111/j.1533-2500.2011.00526.x, 22226400.
26. Canadian Agency for Drugs and Technology in Health Abuse and Misuse Potential of Pregabalin: A Review of the Clinical Evidence. 24 April 2012. [http://dpic.org/sites/default/files/PregabalinAbuse_CADTH_24Apr2012.pdf], Canadian Agency for Drugs and Technology in Health.
27. Häuser W, Bartram-Wunn E, Bartram C, Reinecke H, Tölle T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 2011, 152:1709-1717. 10.1016/j.pain.2011.01.050, 21429668.
28. Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol 2012, 30:78-87.
29. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005, 53:519-527. 10.1002/art.21319, 16082646.
30. Russell IJ, Kamin M, Bennett RM, Schnitzer TJ, Green JA, Katz WA. Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 2000, 6:250-257. 10.1097/00124743-200010000-00003, 19078481.
31. Tofferi JK, Jackson JL, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004, 51:9-13. 10.1002/art.20076, 14872449.
32. Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol 2011, 38:2653-2663. 10.3899/jrheum.110194, 21885490.
33. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005, 52:2495-2505. 10.1002/art.21191, 16052595.
34. Painter JT, Crofford LJ, Talbert J. Geographic variation of chronic opioid use in fibromyalgia. Clin Ther 2013, 35:303-311. 10.1016/j.clinthera.2013.02.003, 23485077.
35. Marschall U, Arnold B, Häuser W. Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009. Schmerz 2011, 25:402-404. 406-410. In German, 10.1007/s00482-011-1079-3, 21818719.
36. Callejas Rubio JL, Fernández Moyano A, Navarro Hidalgo D, Palmero Palmero C. [Percutaneous fentanyl in fibromyalgia]. Med Clin (Barc) 2003, 120:358-359. In Spanish.
37. Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y. Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat 2013, 2013:898493. 3614030, 23577251.
38. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol 2013, 19:72-77. 10.1097/RHU.0b013e3182863447, 23364665.
39. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O'Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C. American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009, 10:113-130. 10.1016/j.jpain.2008.10.008, 19187889, American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel.
40. Ramiro S, Radner H, van der Heijde DM, Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl 2012, 90:47-55. 10.3899/jrheum.120342, 22942329.
41. Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008, 9:164-173. 10.1016/j.jpain.2007.09.002, 17974490.
42. Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 2010, 110:604-610. 10.1213/ANE.0b013e3181c76f70, 20007734.
43. Ware MA, St Arnaud-Trempe E. The abuse potential of the synthetic cannabinoid nabilone. Addiction 2010, 105:494-503. 10.1111/j.1360-0443.2009.02776.x, 20402993.
44. Cuatrecasas G, Alegre C, Fernandez-Solà J, Gonzalez MJ, Garcia-Fructuoso F, Poca-Dias V, Nadal A, Cuatrecasas G, Navarro F, Mera A, Lage M, Peinó R, Casanueva F, Liñan C, Sesmilo G, Coves MJ, Izquierdo JP, Alvarez I, Granados E, Puig-Domingo M. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain 2012, 153:1382-1389. 10.1016/j.pain.2012.02.012, 22465047.
45. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998, 104:227-231. 10.1016/S0002-9343(97)00351-3, 9552084.
46. Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 2010, 95:4331-4337. 10.1210/jc.2010-0061, 20631018.
47. Calandre EP, Rico-Villademoros F. The role of antipsychotics in the management of fibromyalgia. CNS Drugs 2012, 26:135-153. 10.2165/11597130-000000000-00000, 22296316.
48. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 2012, 3:1-14.
49. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum 2013, 65:529-538. 10.1002/art.37734, 23359310.
50. Smith B, Peterson K, Fu R, McDonagh M, Thakurta S. Drug Class Review: Drugs for Fibromyalgia: Final Original Report [Internet]. Portland (OR): Oregon Health & Science University. 2011, [http://www.ncbi.nlm.nih.gov/books/NBK55552/].
51. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P. Comptive efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 2013, 72:955-962. 10.1136/annrheumdis-2011-201249, 22739992.
52. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatology (Oxford) 2010, 49:706-715.